In tumors, hypoxic regions are common due to the rapid proliferation of cancer cells outpacing their blood supply. HIF-1 activation in these regions promotes angiogenesis through the induction of VEGF, enhancing the blood supply to the tumor and supporting its growth. Additionally, HIF-1 can modulate the metabolic switch to anaerobic glycolysis, allowing cancer cells to survive in low oxygen environments. This makes HIF-1 a potential target for cancer therapy.
